Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05148780 · ClinicalTrials.gov registry record · Early Phase 1
A Study of Acute Respiratory Infections in Global Outpatient Setting
A Early Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 245
- Enrollment target
NCT05148780: Completed Early Phase 1 study, sponsored by Janssen Research & Development.
NCT05148780 is a Early Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 245 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (362% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05148780, a Early Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 245 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the positivity rate of respiratory syncytial virus (RSV), influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in high-risk participants presenting with acute respiratory infections (ARIs) in outpatient settings during the influenza/RSV season and to evaluate the association between lower respiratory tract disease (LRTD) and ARI-related hospitalization in participants positive for RSV.
Primary Outcome
Percentage of participants positive for RSV, among those screened for viral pathogens using a polymerase chain reaction (PCR)-based test will be reported.
Interventions
- DIAGNOSTIC_TEST Nasal Swab Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2021-12-20 |
| Est. Completion | 2023-02-22 |
| Phase | Early Phase 1 |
What the finished NCT05148780 record still lists
NCT05148780 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (362% higher).
The record links to 0 conditions, and to 1 intervention - of which Nasal Swab Sample is the first listed.
NCT05148780 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05148780 about?
NCT05148780 is a clinical study titled "A Study of Acute Respiratory Infections in Global Outpatient Setting". The purpose of this study is to evaluate the positivity rate of respiratory syncytial virus (RSV), influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in high-risk participants presenting with acute respiratory infections (ARIs) in outpatient settings during the influenz...
What is the current status of trial NCT05148780?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 245 participants. The study started on 2021-12-20. Estimated completion is 2023-02-22.
What interventions are being tested in trial NCT05148780?
The interventions under investigation include: Nasal Swab Sample (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05148780?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05148780's enrollment target sits among peer trials
245 48th of 2000 higher than 1,952 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI